$46.1M in expenses

During fy24, arkansas children's research institute (ACRI) received $53 million from federal, state, and private agencies, industry sponsors, and philanthropic donations to support research to advance knowledge that will guide the way injury and illness are prevented and treated in children. The research funding included $10 million in state opioid settlement funding to establish the national center for opioid research and clinical effectiveness. In 2024, two research programs at ACRI were recognized by national geographic highlighted in its "7 breakthroughs that changed medicine in 2024" the heart research program was recognized for work on partial heart transplants as replacement heart valves that continue to grow with children and the allergy and immunology program was recognized for its contributions to the first drug approved by the FDA to treat multiple food allergies, omalizumab. Overall, ACRI provided the research infrastructure to over 150 researchers who published their scientific findings in over 407 peer-reviewed scientific journal articles, of which 24.2% of the publications appeared in the top 10% ranking journals.